Latest Australian Manufacturing News

Page 1 of 7
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
SIV Capital has agreed to acquire underground mining equipment group PPKME in a proposed scheme valued at about $18.6 million. The transaction could finally give SIV an operating business and a route back to ASX trading, but it still faces funding, shareholder, court and listing hurdles.
Victor Sage
Victor Sage
12 Nov 2026
AdAlta has received a larger-than-expected A$1.396 million R&D Tax Incentive refund tied to overseas work on its EW-001 CAR-T therapy. The non-dilutive cash arrives before Australian manufacturing and expected FDA pre-IND meeting minutes in December.
Ada Torres
Ada Torres
12 Nov 2026
Li-S Energy says its lithium-sulfur technology moved closer to commercialisation in 2026, with new Power Cells, defence testing and a nearly two-hour drone flight. The company is now planning the next manufacturing step while holding $15.0 million in cash.
Victor Sage
Victor Sage
10 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Nutritional Growth Solutions has cut quarterly net operating cash outflow by 54% while completing its Sprout Organic acquisition just after quarter end. The enlarged group starts with US$1.613 million in cash, no borrowings and a substantially larger share base.
Victor Sage
Victor Sage
30 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026
BlueScope Steel has raised its 1H FY2027 underlying EBIT guidance to approaching $1.1 billion, well above its previous $860 million to $960 million range. Stronger US steel spreads are driving the upgrade, with Australian demand also exceeding expectations.
Victor Sage
Victor Sage
26 Oct 2026
AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.
Ada Torres
Ada Torres
19 Oct 2026
BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.
Victor Sage
Victor Sage
15 Oct 2026
Delorean Corporation has secured a non-binding $20 million financing mandate from Westpac for its NSW1 Horsley Park bioenergy project, taking identified funding to about 81% of the estimated build cost. The project still needs binding finance documents and a further $11.6 million before financial close can be reached.
Victor Sage
Victor Sage
13 Oct 2026
AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.
Ada Torres
Ada Torres
5 Oct 2026

Browse the archive

Full archive